Yi Yang

Yi Yang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2025 in mAbs
Verified
Journal Article
Open access
MSMonica Sadek
Monica Sadek
NMNeelima Mantha
Neelima Mantha
SLSteffen Lippold
Steffen Lippold
DLDelia Li
Delia Li
KSKyle Spitler
Kyle Spitler
YYYi Yang
Yi Yang
Bispecific antibodies (bsAbs) target two distinct binding sites, which enable novel mechanisms of action for the treatment of disease. Due to this structural complexity, bsAbs exhibit greater heterogeneity as compared to monospecific antibodies and may require nonstandard purification strategies to remove undesired product-related impurities. However, the implementation of unique manufacturing processes may result in the observation of new impurities. When new impurities are identified, comprehensive characterization of these species is needed to understand the potential impact to the safety and efficacy of the product. In this study, the assessment of a unique purification mode, protein L affinity chromatography, for purification of a bsAb resulted in high levels of free light chain (LC) in the final product. It was discovered that the free LC formed oligomers of various sizes upon accelerated stress in a concentration-, time-, and temperature-dependent manner. This is the first time free LC oligomer has been reported as a product-related impurity. Characterization of the free LC and free LC oligomer species was performed using a variety of chromatographic, electrophoretic, and mass spectrometry tools to gain insight on the formation and behavior of these impurities in the product. These studies informed an impact assessment of the observed free LC and free LC oligomer species on safety, immunogenicity, pharmacokinetics, and bioactivity.

11 September 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ZHZhiqi Hao
Zhiqi Hao
CYChristopher Yu
Christopher Yu
ABAnja Bathke
Anja Bathke
JYJack Yim
Jack Yim
ABAlexander Buettner
Alexander Buettner
YYYi Yang
Yi Yang
The increasing complexity of modern protein therapeutics and the demand for faster development of new therapeutics require not only advanced analytical tools that provide in-depth understanding of the product quality attributes (PQAs) that are crucial for safety and efficacy but also the implementation of a control strategy to ensure that the released drug product meets the desired quality profile. The multi-attribute method (MAM), a liquid chromatography–mass spectrometry (LC-MS) approach, has emerged as a transformative solution that provides site-specific monitoring of multiple critical quality attributes (CQAs) in a single workflow, replacing several conventional profile-based assays. The MAM achieves comprehensive quality oversight through two primary mechanisms: targeted attribute quantitation (TAQ) for the simultaneous quantification of predefined known modifications, and new peak detection (NPD) for identifying unforeseen impurities, thereby establishing a robust, “double-layered” control strategy. This article reviews the practical challenges and current industry practices for successfully implementing the MAM within current good manufacturing practice (cGMP) environments. The successful transition of the MAM from a specialized characterization tool to a validated quality control (QC) cornerstone relies on a framework built upon four foundational pillars: stringent instrument qualification paired with compliance-ready informatics, proactive and strictly scheduled instrument maintenance, rigorous system suitability testing (SST), and phase-appropriate method validation and transfer. The challenges of global method transfer and the solutions to mitigate inter-laboratory variability are discussed. Finally, the review explores the emerging trends shaping the future of the MAM in QC and the critical role of the MAM in facilitating real-time release testing (RTRT) in next-generation autonomous manufacturing.